Trial
NCT05574166
A Phase I Study to Evaluate Safety and Pharmacokinetics of Escalating Single Doses and Multiple Doses of SP-8356
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Shin Poong Pharmaceutical Co. Ltd.
Collaborators
—
Condition
Atherosclerosis
Intervention
SP-8356
Why stopped
Only Part 1 was conducted but not Part 2. Due to the low exposures, definitive safety conclusions could not be made for the targeted exposure levels in the future.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-10-10